Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 2 | 1997 | 6 | 0.270 |
Why?
|
| Seizures | 4 | 2012 | 279 | 0.240 |
Why?
|
| Anticonvulsants | 5 | 2007 | 223 | 0.220 |
Why?
|
| Epilepsy, Generalized | 1 | 1997 | 15 | 0.150 |
Why?
|
| Pergolide | 1 | 1997 | 12 | 0.150 |
Why?
|
| Tourette Syndrome | 1 | 1997 | 8 | 0.150 |
Why?
|
| Standard of Care | 1 | 2017 | 22 | 0.150 |
Why?
|
| Mitochondrial Diseases | 1 | 2017 | 24 | 0.150 |
Why?
|
| Dopamine Agonists | 1 | 1997 | 68 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1997 | 106 | 0.140 |
Why?
|
| Valproic Acid | 1 | 1997 | 93 | 0.140 |
Why?
|
| Meningoencephalitis | 1 | 1994 | 6 | 0.120 |
Why?
|
| Amebiasis | 1 | 1994 | 6 | 0.120 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1994 | 26 | 0.120 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 1994 | 20 | 0.120 |
Why?
|
| Electroconvulsive Therapy | 1 | 1997 | 402 | 0.110 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Hallucinations | 1 | 2012 | 19 | 0.100 |
Why?
|
| Borrelia burgdorferi | 1 | 2012 | 11 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 1994 | 233 | 0.100 |
Why?
|
| Child | 9 | 2012 | 6405 | 0.100 |
Why?
|
| Neurology | 1 | 2012 | 43 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2012 | 94 | 0.100 |
Why?
|
| Child, Preschool | 7 | 2010 | 3187 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 109 | 0.090 |
Why?
|
| Epilepsy | 3 | 2007 | 336 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2012 | 383 | 0.080 |
Why?
|
| Decision Making | 1 | 2012 | 410 | 0.080 |
Why?
|
| Neuralgia | 1 | 2007 | 27 | 0.070 |
Why?
|
| Infant | 5 | 2010 | 2891 | 0.070 |
Why?
|
| Male | 11 | 2012 | 37321 | 0.060 |
Why?
|
| Cerebral Angiography | 2 | 1994 | 151 | 0.060 |
Why?
|
| Humans | 14 | 2017 | 68618 | 0.060 |
Why?
|
| Vagus Nerve | 1 | 2003 | 90 | 0.050 |
Why?
|
| Female | 9 | 2012 | 38074 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2003 | 147 | 0.050 |
Why?
|
| Adolescent | 4 | 2003 | 8912 | 0.050 |
Why?
|
| Age of Onset | 2 | 2007 | 188 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2012 | 7277 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2010 | 2223 | 0.040 |
Why?
|
| Registries | 1 | 2003 | 733 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2012 | 7029 | 0.040 |
Why?
|
| Electroencephalography | 2 | 2007 | 418 | 0.040 |
Why?
|
| Pedigree | 2 | 2010 | 159 | 0.040 |
Why?
|
| Fructose | 1 | 1999 | 51 | 0.040 |
Why?
|
| Syndrome | 2 | 2010 | 255 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1140 | 0.040 |
Why?
|
| Cerebral Palsy | 1 | 1997 | 24 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2007 | 2455 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 1851 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1999 | 782 | 0.030 |
Why?
|
| Psychometrics | 1 | 1999 | 514 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 248 | 0.030 |
Why?
|
| Amoeba | 1 | 1994 | 1 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1999 | 1745 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 1997 | 342 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 1994 | 107 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1994 | 282 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1999 | 659 | 0.030 |
Why?
|
| Carotid Stenosis | 1 | 1994 | 163 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 567 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2012 | 32 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2012 | 47 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 219 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2010 | 32 | 0.020 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2010 | 43 | 0.020 |
Why?
|
| Eye Movements | 1 | 2010 | 44 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 164 | 0.020 |
Why?
|
| Age Factors | 1 | 1995 | 1864 | 0.020 |
Why?
|
| Family | 1 | 2010 | 293 | 0.020 |
Why?
|
| NAV1.7 Voltage-Gated Sodium Channel | 1 | 2007 | 1 | 0.020 |
Why?
|
| Nociceptors | 1 | 2007 | 9 | 0.020 |
Why?
|
| Sleep Apnea, Central | 1 | 2007 | 6 | 0.020 |
Why?
|
| Jaw | 1 | 2007 | 4 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2007 | 24 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1342 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2007 | 51 | 0.020 |
Why?
|
| Flushing | 1 | 2007 | 7 | 0.020 |
Why?
|
| Ganglia, Spinal | 1 | 2007 | 29 | 0.020 |
Why?
|
| Rectum | 1 | 2007 | 62 | 0.020 |
Why?
|
| Bradycardia | 1 | 2007 | 45 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2007 | 42 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2007 | 67 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2007 | 64 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 161 | 0.020 |
Why?
|
| Eye | 1 | 2007 | 89 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2007 | 113 | 0.020 |
Why?
|
| Analgesics | 1 | 2007 | 118 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 1213 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 1026 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 2334 | 0.020 |
Why?
|
| Phenotype | 1 | 2007 | 947 | 0.010 |
Why?
|
| Brain | 1 | 1994 | 2176 | 0.010 |
Why?
|
| Adult | 3 | 2010 | 21403 | 0.010 |
Why?
|
| Behavioral Symptoms | 1 | 1999 | 32 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1999 | 51 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 579 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1999 | 142 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2003 | 2358 | 0.010 |
Why?
|
| Animals | 1 | 1994 | 20881 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 3259 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1999 | 955 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 4655 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1753 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1999 | 3705 | 0.010 |
Why?
|
| Aged | 1 | 2003 | 14862 | 0.000 |
Why?
|
| Middle Aged | 1 | 2003 | 21147 | 0.000 |
Why?
|